Replacement of a single residue in an antibody completely abolishes cognate antigen binding, as predicted by theoretical methods

Structural insights into the interaction between antibodies and antigens at the atomic level are pivotal for understanding the molecular mechanisms of antigen binding. Despite the availability of structural models generated by recent artificial intelligence advancements, computational predictions require experimental validation to confirm their accuracy. Here, we demonstrate a novel approach that combines computational protein modeling with spectroscopic experiments to validate antibody-antigen interactions. As a case example we use solanezumab, a monoclonal antibody that targets amyloid-beta (A{beta}), whose misfolding is the main factor responsible for Alzheimers disease. For this antibody we predicted a single mutation, G95AHC, within the paratope of the heavy chain to disrupt antigen binding. This mutation, referred to as a "dead mutant", was experimentally validated using an immuno-infrared biosensor (iRS). Our results confirmed that the mutation abolished antigen binding without affecting the native structure of the antibody. The use of dead mutants enables precise differentiation between specific and nonspecific binding, which is particularly important in medical diagnostics. We applied this approach to analyze the binding of solanezumab to synthetically produced A{beta} variants and A{beta} catched by the iRS functionalized surface from cerebrospinal fluid, showcasing its utility in Alzheimers disease diagnostics. These findings highlight the value of computational modeling and experimental validation in understanding antigen-antibody interactions, with significant implications for diagnostic and therapeutic applications.